Last reviewed · How we verify

Tandospirone + Amlodipine — Competitive Intelligence Brief

Tandospirone + Amlodipine (Tandospirone + Amlodipine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT1A agonist + dihydropyridine calcium channel blocker. Area: Psychiatry/Neurology; Cardiovascular.

marketed 5-HT1A agonist + dihydropyridine calcium channel blocker 5-HT1A receptor; L-type calcium channel Psychiatry/Neurology; Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Tandospirone + Amlodipine (Tandospirone + Amlodipine) — Chongqing Medical University. Tandospirone acts as a 5-HT1A receptor agonist for anxiety, while amlodipine is a calcium channel blocker for hypertension and angina.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tandospirone + Amlodipine TARGET Tandospirone + Amlodipine Chongqing Medical University marketed 5-HT1A agonist + dihydropyridine calcium channel blocker 5-HT1A receptor; L-type calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT1A agonist + dihydropyridine calcium channel blocker class)

  1. Chongqing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tandospirone + Amlodipine — Competitive Intelligence Brief. https://druglandscape.com/ci/tandospirone-amlodipine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: